Madden Securities’s Alaunos Therapeutics TCRT Stock Holding History

Madden Securities’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-27	Closed	-$2.6K	–	329
2022 Q4	$2.6K	Buy	+27	New	+$3.91K	﹤0.01%	365

Other funds holding TCRT

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Madden Securities's TCRT Position: Q1 2023 in Review

Madden Securities sold out of Alaunos Therapeutics (TCRT) in Q1 2023, closing a stake of 27 shares — an estimated $2.6K sold.

Madden Securities first reported a position in TCRT in Q4 2022 and held it in 1 quarter. The position peaked at $2.6K in Q4 2022. 108 funds tracked by Wall St. Rank hold TCRT as of Q1 2023.

Madden Securities reported no remaining Alaunos Therapeutics position as of Q1 2023 after selling out during the quarter.
Madden Securities sold 27 Alaunos Therapeutics shares in Q1 2023, an estimated $2.6K.
Madden Securities first reported a position in Alaunos Therapeutics in Q4 2022 and held it in 1 quarter.
Madden Securities's Alaunos Therapeutics position peaked at $2.6K in Q4 2022.
108 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2023.

Based on Madden Securities's 13F filing for Q1 2023, filed 21 Apr 2023.